Abstract: An objective of the present invention is to provide a method for producing cosmetic products capable of improving a touch of cosmetic products containing powder and exerting the function of the powder sufficiently. In order to accomplish the objective described above, a method for producing cosmetic products according to the invention comprises a use of a media-agitating mill to disperse powder components and oil components or aqueous components. A method for producing cosmetic products according to the invention is applied to powdery cosmetic products, oily cosmetic products, emulsified cosmetic products and lipsticks. A method for producing cosmetic products involving a step for imparting a particle with hydrophobicity using a media-agitating mill is also provided. Furthermore, a method for producing cosmetic products using hydrophobicity-imparted powdery dispersion containing organically-denatured clay mineral is provided.

Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: A method for preparing a calcium phosphate pasty material for injection which after, setting, is designed to form an apatite material consists in: producing from water and calcium phosphates pasty mixture capable of developing, hardening and forming a hydroxyapatite. The method is characterised in that it consists in adding to the calcic phosphates or to the pasty mixture before it is injected a methicone having relative to the mixture more than 0.30 wt. % and less than 10 wt. %. The resulting material can be injected, that is it can be transported in pasty form into a conduit under moderate pressure levels. The material sets on the site of implantation and hardens to form an apatite biomaterial in a manner similar to known methicone-free calcium phosphate mixtures.

Abstract: A penetrating antibiotic gel for treating pain, inflammation and other pathological conditions affecting musculoskeletal tissues and other soft tissues of the body. The composition includes an antibiotic compound and a mobilizing agent in an amount sufficient to enable the antimicrobial compound to penetrate into the sub-dermal soft tissues. The antimicrobial compound may be a macrolide antibiotic compound such as azithromycin, erythromycin or roxithromycin, for example, and the mobilizing agent may be an organogel compound, such as pluronic lecithin liposomal organogel (PLO). The composition may further include a penetration enhancing adjuvant, such as d-limonene, for example. The composition may be applied topically so as to penetrate into the sub-dermal soft tissues, or may injected so as to be absorbed into the soft tissues locally.

Abstract: Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds by applying a compound comprised of a liquid medium comprising an azide and an azide stabilizer. The azide can be selected from the group consisting of sodium azide and potassium azide or a combination of the two. The composition provides an effective pesticide, without causing significant harm to the environment. The composition may be applied to soil to control a population of a deleterious organism.

Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the cellulose dissolves in the aqueous solution setting of the calcium phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.

Abstract: Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.

Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceutical excipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceutical excipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.

Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.

Abstract: The invention relates to a method for reducing the bromide content in an aqueous bromide-containing solution using hydrogen peroxide.

Abstract: The invention concerns the use, in an aqueous spray mixture comprising a phytosanitary formulation, of an anti-leaching agent comprising: at least a polyhydroxyl and/or polycarboxyl polymer or copolymer; at least a crosslinking agent comprising a metal selected among columns IVA, IB and IIIB of the periodic table; said anti-leaching agent being, in the aqueous spray mixture, in the form of an aqueous solution or dispersion having a polymer or copolymer concentration such that the viscosity of the anti-leaching agent is not more than 10 times the viscosity of the aqueous solution in polymer or copolymer without crosslinking agent, having the same concentration.

Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.

Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.

Abstract: This invention provides pharmaceutical compositions comprising TGF-&bgr;.

Abstract: A method of dyeing and treating a substrate using a water-stabilized organosilane. A method of antimicrobially treating a food article. A method of antimicrobially coating a fluid container. A method of antimicrobially coating a latex medical article.

Abstract: The invention relates to a pharmaceutical implant for controllably releasing a drug in a subject and methods for manufacturing and administering the implant. The implant is made of associated microparticles of a drug dispersed in a biodegradable polymer. The microparticles are sufficiently associated so that the implant maintains a predetermined shape but are not fused together so as to form a single monolithic structure. The drug can be controllably released in a subject by administration of the pharmaceutical implant without the need of a suspending fluid.

Abstract: A method for the controlled release of an active principle contained in a multiple water-in-oil-in-water emulsion characterized in that the multiple emulsion comprises an invert emulsion Ei with an aqueous phase A1 containing at least a hydrophilic active principle. The emulsion Ei is dispersed in the form of direct emulsion droplets Ed, in a continuous aqueous phase A2, with the two emulsions Ed and Ei stabilized by at least a surfactant, present in their respective continuous phases. The multiple emulsion is brought in the presence of an effective amount of an agent for transforming it into a direct emulsion and induce the release of the active principle, contained in the aqueous phase A1 of emulsion Ei, in the aqueous phase A2.

Abstract: A swallowable, solid dose form composition for treating upper gastrointestinal tract distress containing bismuth subsalicylate, carbonate or bicarbonate salt, disintegrating agent, anionic or nonionic surfactant, and microcrystalline cellulose is described.

Abstract: A mating disruption method for the control of insect pests comprises releasing a sex pheromone in a field wherein an adsorption of the sex pheromone to a soil in the field is decreased.

Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the cellulose dissolves in the aqueous solution setting of the calcium phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.

Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.

Abstract: Disclosed herein is a tableted oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: The invention provides a method for preparing a wound dressing, comprising activating a textile carrier to form between about 0.026 and 0.06 mg-equiv. of aldehyde groups per gram of carrier, impregnating the activated carrier in a solution of at least one bioactive enzyme and drying the same, whereby there is produced a wound dressing from which the bioactive enzyme is releasable in effective amounts for a period of at least 3 days upon the dressing being brought into contact with a moist surface.

Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceutical excipient, to the formulation.

Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).

Abstract: The invention relates to an injectable curable bone cement paste based on bioresorbable hydroxyapatite-like compounds comprising calcium phosphate, which contains a cationic antibiotic in the form of a salt, preferably of its sulfate, the curable biodegradable bone cement releasing the antibiotic in biologically active concentrations with depot-like action over a long period of time. The bone cements according to the invention are suitable for the treatment of infectious inflammations of the bone and of the bone marrow, in particular as a result of bone defects and bone fractures.

Abstract: The present invention provides devices and methods for stabilizing bicarbonate-based solutions for peritoneal dialysis or hemofiltration. The bicarbonate-based solutions of the present invention are formulated and stored in at least two parts—an alkaline bicarbonate concentrate and an acidic concentrate. The alkaline bicarbonate concentrate is adjusted to have a pH of about 8.6 to 10.0. The acidic concentrate is adjusted to have a stable, acidic pH ranging from about 1.0 to 3.0. Upon mixing, although some variation in the pH of the mixed bicarbonate solution exists, the inventors have discovered that with the appropriate selection of the parameters of the concentrates, the pH of the mixed solution is always within an acceptable physiological range.

Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.

Abstract: Tungsten and molybdenum oxide, and oxides of other metals and bronzes derived from such oxides, constitute a broad class of materials having applications as photochromic sunblock/cosmetics. These materials are well known in the prior art in the context of photochromic optical data storage media and they offer an excellent match with the very properties needed for cosmetic applications. The invention relates to the adaptation of the class of tungsten and molybdenum oxide photochromics to sunblocking/dosimetry, energy storage, and cosmetic coloration. In addition, certain naturally occurring proteins which exhibit the necessary photochromism can also be used alone for the same purpose or with the oxide systems described above.

Abstract: The present invention is directed to bioactive compositions that induce the repair of damaged or diseased connective tissues upon contact of the damaged or diseased tissues with the composition in vivo. More particularly the present invention is directed to the use of compositions comprising an effective amount of bone sialoprotein to enhance the repair of damaged or diseased bone.

Abstract: A disinfectant composition containing more than 0.05% and less than 9.4% by volume of dimethyl benzyl lauryl ammonium bromide, substantially pure, substantially de-ionized, substantially bacteria free water if the pH of the water is between 5.0 and 6.8, a first stabilizer structured to adjust a pH level of the disinfectant composition to approximately 7, ammonium Bulfate structured to increase a strength of the composition and a stabilizer structured to lower the pH level of the disinfectant composition back to approximately 7.

Abstract: The present invention provides a composition for attracting scarabs. Liquid and solid formulations are provided, along with methods for their use, for controlling or eliminating scarabs, and/or protecting plants susceptible to scarab damage.

Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The .compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.

Abstract: Dry, stable, high available halogen sanitizing granular compositions with a rapid rate of dissolution comprising halogenated 1,3,5-triazine-2,4,6-triones and a dissolution accelerant that is an alkali metal salt of 1,3,5-triazine-2,4,6-trione are disclosed. The disclosed compositions may include inorganic and/or organic disintegration agents. Additionally, these compositions may contain other performance enhancing additives such as water clarifiers, algaestats/algaecides, surfactants, glidants, processing aids, and binders. These UV stable sanitizing compositions contain a high available halogen content, and are stable even when stored in high-humidity environments.

Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceuticalexcipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceuticalexcipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.

Abstract: A blank tablet of this invention, typically, includes an absorbent, a disintegrant, a lubricant, and a diluent or a binder, or a mixture of a diluent and a binder. An active ingredient in liquid form is introduced into the blank tablet to produce a pharmaceutical composition.

Abstract: An aqueous pourable liquid composition comprising a high concentration of sodium alginate and an alkali metal bicarbonate, wherein the sodium alginate has an average mannuronic acid residue to guluronic acid residue ratio of at least 0.6:1. In addition, an alginate or alginic acid for forming a protective coating on gastrointestinal mucosal tissue, use of and compositions including the same are provided.

Abstract: A storage stable magnesium oxychloride coated granular animal feed mineral supplement composition resistant to disintegration cause by moisture absorption and attrition, comprising granular mineral nutrients useful as animal feed supplements and magnesium oxychloride coatings amounting to between 0.5 and 10.0 percent of the weight of the granules, formed on the granules of mineral nutrients by coreaction of magnesium chloride and magnesium oxide. An additional coating of between 0.2 and 2.0 percent magnesium stearate formed on the magnesium oxychloride may be used to decrease the rate of wetting of the granular animal feed mineral supplements.

Abstract: The present invention provides a sterol, stanol or their corresponding acid ester in a form suitable for the manufacture of an oral dosage form. A method for producing the oral dosage form is also provided.

Abstract: A formulation for preventing or treating parturient hypocalcemia or milk fever comprises a solution of hydrochloric acid in water, soybean meal, additional feed components and minerals. The feed formulation is prepared by grinding soybean meal to a particle size of 1000 to 2000 microns. A hydrochloric acid solution and feedgrade limestone are blended into the meal to produce the formulation.

Abstract: Piece-form materials which comprise 5-100% by mass calcium formate and 95-0% by mass additives and have particle sizes of 0.2-5 mm can be prepared from finely crystalline calcium formate and the additives by compression and, if necessary, subsequent comminution and/or fractionation to set the particle size.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a silicone hydrogel lens by plasma treating the lens and subsequently heating the lens in an aqueous solution containing a surface-protective agent.

Abstract: A thixotropic, non-cytotoxic, topical hydrogel that contains a proven safe and effective, broad spectrum, antimicrobial agent based on a unique electrolytically derived sodium hypochlorite solution.

Abstract: The invention includes a patch and method for transdermal delivery of bupropion base. In the method of this invention, a patient is administered a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient or to treat obesity. A transdermal patch includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

Abstract: Thus, this invention provides novel, synthetic polypeptide vaccines against human melanoma and methods for making these vaccines. Polynucleotides encoding these polypeptides are further provided herein. These compositions are useful as melanoma caccinies and in adoptive immunotherapy.

Abstract: The present invention relates to stable aqueous formulations of the insect repellent ethyl 3-(N-butyl-acetamino)propionate.

Abstract: Aqueous endosulfan microcapsule dispersions in which the dispersed microcapsules comprise endosulfan, an organic solvent or solvent mixture and a capsule-forming material based on isocyanate prepolymers and the aqueous phase which represents the dispersion medium comprises surfactants, a water-soluble inorganic salt with or without other formulation aids, which include a relatively small amount of capsule-forming material, and a process for their preparation.

Abstract: The invention includes an apparatus and method for transdermal delivery of bupropion base. In the method of this invention, patient is administered parenterally a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient. A transdermal delivery system includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

Abstract: A liquid pesticidal composition, which is substantially free of water, comprising a hydrophobic pesticide or mixture of pesticides dissolved in an organic solvent and comprising as surfactants (a) a castor oil ethoxylate having 30-50 mol ethoxylate, (b) a branched C8-C18 alcohol ethoxylate having 5-10 mol ethoxylate, and (c) a tristyrenephenol-ethoxylate having 8-30 mol ethoxylate, or its phosphate or salt thereof. The compositions also include gels having a viscosity of 500 to 20,000 mPas and comprising additionally a gelling agent.

Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.